Evidence that platelet-activating factor suppresses uterine oxytocin-induced 13,14-dihydro-15-keto-prostaglandin F2 alpha release and phosphatidylinositol hydrolysis in the ewe.
This study was conducted to determine whether platelet-activating factor (PAF) (1) attenuated oxytocin-induced secretion of the prostaglandin (PG) F2 alpha metabolite, PGFM, by the ovine uterus in situ and (2) inhibited the generation of the inositol phosphate secondary messengers by endometrial tissue in response to oxytocin challenge in vitro. Ovariectomized ewes received steroid replacement to mimic the luteal phase. Six ewes received intrauterine injections of 200 micrograms PAF/uterine horn/day on Days 11-15, and 6 ewes were treated with vehicle. All ewes received 1 microgram oxytocin i.v. on Days 13-16. Pretreatment of ewes with PAF significantly suppressed PGFM release in response to oxytocin on Days 14 and 15 (p less than 0.005) compared to vehicle-treated ewes. PAF was not administered on Day 16, and the PGFM response to oxytocin was not different between groups. In a second experiment, ewes were given intrauterine injections of 200 micrograms PAF/uterine horn/day (n = 8) or vehicle (n = 7) on Days 11-15, and all ewes received 1 microgram oxytocin i.v. on Days 13 and 14. On Day 15 the uterus was removed, and the incorporation of 3H-inositol into inositol phosphates was determined in caruncular endometrium. Treatment of ewes with PAF in vivo reduced inositol monophosphate (IP1) generated by oxytocin (10(-6) M) by 56.4%, compared to that in endometrium from vehicle-treated controls, and also inhibited the incorporation of 3H-inositol into glycerophosphoinositol (GPI). If PAF was added to the endometrium during the incubation in vitro, the attenuation of inositol phosphate generation did not occur.(ABSTRACT TRUNCATED AT 250 WORDS)
Battye
K M
KM
Human Reproduction Unit, Royal North Shore Hospital, St. Leonards, NSW, Australia.
O'Neill
C
C
Evans
G
G
D000818:Animals; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000378:metabolism; D004717:Endometrium / Q000187:drug effects / Q000378:metabolism; D005260:Female; D006868:Hydrolysis; D007267:Injections; D007294:Inositol / Q000378:metabolism; D007295:Inositol Phosphates / Q000378:metabolism; D010052:Ovariectomy; D010121:Oxytocin / Q000494:pharmacology*; D010716:Phosphatidylinositols / Q000378:metabolism*; D010972:Platelet Activating Factor / Q000008:administration & dosage / Q000494:pharmacology*; D011863:Radioimmunoassay; D015290:Second Messenger Systems / Q000502:physiology; D012756:Sheep; D014316:Tritium; D014599:Uterus / Q000187:drug effects* / Q000378:metabolism*
D007295:Inositol Phosphates; D010716:Phosphatidylinositols; D010972:Platelet Activating Factor; D014316:Tritium; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D007294:Inositol; D010121:Oxytocin; D015237:Dinoprost